Drugs / MEM 1003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00374920 | Sep → Dec 2006 | bipolar I disorder | Memory Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00257673 | Nov 2005 → Oct 2007 | Alzheimer disease | Memory Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEM 1003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00257673 ↗ |
| Action | Inhibit | “It inhibits L-type Ca2+ channels” NCT00257673 ↗ |
| Modality | Small molecule | “MEM 1003 is the (+)-enantiomer of a dihydropyridine that has been optimized for central nervous system activity.” NCT00257673 ↗ |